Every 424B that Contineum Therapeutics, Inc. (CTNM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics supplements its shelf registration to permit “at the market” sales of up to $100,000,000 of Class A common stock through Leerink Partners under an amended sales agreement. The amendment follows prior Sales Agreement activity: 3,241,110 shares were issued for gross proceeds of approximately $19.6 million as of March 5, 2026.
The prospectus supplement states Leerink Partners will act as sales agent (commission up to 3.0%), sales may occur from time to time at prevailing market prices, and the offering is exclusive of amounts previously sold. Shares outstanding used for illustration: 31,236,787 Class A and 6,083,338 Class B as of December 31, 2025.
Contineum Therapeutics, Inc. is offering 7,346,938 shares of its Class A common stock at a public price of $12.250 per share, for gross proceeds of $89,999,991 before fees and expenses. After underwriting discounts and estimated costs, the company expects net proceeds of approximately $84.2 million, or approximately $96.9 million if underwriters fully exercise their 30‑day option to buy up to 1,102,040 additional shares.
Contineum is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation and immunology, including lead candidates PIPE‑791 and PIPE‑307. It plans to use the cash, together with existing balances, to advance PIPE‑791, support other research and development, and for general corporate purposes, including potential acquisitions. After this offering, 30,446,111 shares of Class A common stock (or 31,548,151 shares if the option is fully exercised) and 6,083,338 shares of non‑voting Class B common stock will be outstanding, and the company believes this funding will support operations through mid‑2029.
Contineum Therapeutics is offering $75.0 million of its Class A common stock in an underwritten primary equity offering. The company may also grant the underwriters a 30-day option to purchase up to an additional $11.25 million of Class A shares.
As of September 30, 2025, Contineum had 23,099,173 shares of Class A common stock and 6,083,338 shares of non-voting Class B common stock outstanding. The company expects that net proceeds from this offering, combined with existing cash, cash equivalents and marketable securities, will fund operations through mid-2029, with a primary focus on advancing its PIPE-791 program, supporting other research and development, and general corporate purposes, including potential complementary product or technology acquisitions without binding commitments.
Contineum is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation and immunology indications and remains an emerging growth and smaller reporting company. It does not expect to pay cash dividends in the foreseeable future and cautions that future share issuances and sales, including under its at-the-market program after a 30-day pause, could pressure the market price of its Class A common stock.